Stein Jeffrey 4

What Happened
Jeffrey Stein, a director of IDEAYA Biosciences (IDYA), was granted 20,000 derivative shares (reported acquisition value $0.00) on June 16, 2026. The filing reports the award as a grant/award (derivative security) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-16; Form 4 filed: 2026-06-18 (appears timely under Form 4 reporting rules).
• Amount: 20,000 derivative shares acquired at $0.00 (reported value $0).
• Shares owned after transaction: Not specified in the provided summary of this filing.
• Footnote: 100% of the shares subject to the award vest in full on the earlier of (i) the first anniversary of the grant date or (ii) immediately prior to the Annual Meeting following the grant, subject to continued service on the board.
• Transaction type code: A (grant/award/acquisition of derivative securities).

Context
This filing documents a director compensation-related award (a derivative grant with a one-year or meeting-triggered vesting schedule). Because it is a grant rather than a market purchase or sale, it should be viewed as a compensation/retention action rather than a direct buy or sell signaling immediate trading intent.